A

Aclaris Therapeutics
D

ACRS

1.44900
USD
0.06
(4.62%)
Market Closed
Volume
19,647
EPS
-1
Div Yield
-
P/E
-1
Market Cap
156,899,515
OverviewSignalsIdeasNews
Related Instruments
A
ADAP
0.00850
(3.06%)
0.28660 USD
A
AFMD
-0.15020
(-13.65%)
0.94980 USD
A
AGIO
-0.850
(-2.75%)
30.060 USD
A
ALLO
0.02000
(1.19%)
1.70500 USD
ALNY
ALNY
3.98
(1.56%)
259.33 USD
AMGN
AMGN
-2.15
(-0.76%)
281.20 USD
A
AMRN
0.000
(0.00%)
10.990 USD
A
ARWR
0.380
(2.71%)
14.410 USD
A
ASND
5.340
(3.20%)
172.030 USD
B
BEAM
0.400
(2.02%)
20.210 USD
B
BLUE
-0.15000
(-3.69%)
3.91000 USD
BMRN
BMRN
-0.700
(-1.12%)
61.980 USD
C
CAPR
-0.840
(-6.61%)
11.870 USD
C
CRSP
0.520
(1.38%)
38.220 USD
E
EDIT
0.01500
(0.93%)
1.63000 USD
More
News
Treasury Yields Decline as Market Anticipates Fed Rate Cuts

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

8 months ago
Economy News
Novo Nordisk Surges in Profit and Sales

Novo Nordisk Surges in Profit and Sales

1 year ago
Stocks News
More

Title: Aclaris Therapeutics

Sector: Healthcare
Industry: Biotechnology
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Trading. Social. Simple.
FacebookTwitterYoutube
Company
Contact usAbout usTerms Of UsePrivacy PolicyCookies PolicyDisclaimerHelp Center
Social Network
The NetworkSignals NetworkIdeas NetworkBest Traders
Products
Risk CalculatorPip CalculatorAdvance Chart
Markets
Exchange RatesCommodities RatesCryptocurrencies RatesIndices RatesUS Stocks Rates
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.